A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT03922750

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03922750
  • EudraCT 2018-003407-18
Main results
  • Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial Diabetes care, 2021-07 DOI, PubMed 33875485, PMC8323191 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Germany, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03922750. Randomized; no masking; primary purpose treatment. Start 2019-05-09 (actual); primary completion 2019-12-19 (actual). Results posted on 2021-01-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin icodec
Intervention (Drug)
Insulin glargine U100
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03922750
Content hash
f553657bb032570e706c2f9cfdfa07f354536b5c474eb7483b57c39786103121